Loading clinical trials...
Loading clinical trials...
A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors
Conditions
Interventions
BG-68501
Fulvestrant
+1 more
Locations
24
United States
Hoag Memorial Presbyterian
Newport Beach, California, United States
Florida Cancer Specialists and Research Institute
Lake Mary, Florida, United States
Washington University School of Medicine
St Louis, Missouri, United States
Titan Health Partners Llc Dba Astera Cancer Care
East Brunswick, New Jersey, United States
Avera Cancer Institute
Sioux Falls, South Dakota, United States
Mary Crowley Cancer Research
Dallas, Texas, United States
Start Date
March 11, 2024
Primary Completion Date
April 1, 2028
Completion Date
July 1, 2028
Last Updated
April 22, 2026
NCT05671510
NCT07547774
NCT07040891
NCT06964009
NCT03340506
NCT07431827
Lead Sponsor
BeiGene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions